Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hypercholesterolemia: therapeutic approach].

C Alessandri1, F Peverini

  • 1Istituto di I Clinica Medica, Università degli Studi La Sapienza, Roma.

La Clinica Terapeutica
|June 30, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Role of FGF7 in Tumor-Induced Osteomalacia. Clinic-Pathologic Analysis in a Patient with a Sino-Nasal Phosphaturic Mesenchymal Tumor.

Calcified tissue international·2025
Same author

Cryptogenic stroke and seronegative antiphospholipid syndrome: a case series of patients with positivity for "non-criteria" antiphospholipid antibodies.

Reumatismo·2024
Same author

Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort.

Reumatismo·2024
Same author

Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study.

Reumatismo·2022
Same author

Tofacitinib Decreases Autophagy of Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients.

Frontiers in pharmacology·2022
Same author

Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2021
Same journal

Effectiveness of Focal Muscle Vibration in Post-Anterior Cruciate Ligament Reconstruction Rehabilitation: A Case Report.

La Clinica terapeutica·2026
Same journal

Violence Against Women as a Public-Health Exposure: Biological Embedding, Medico-Legal Caution and Precision Prevention in the EpiWe Framework.

La Clinica terapeutica·2026
Same journal

Suicide of the Work-Disabled Individual Affected by Neoplasia with Unfavorable Prognosis: Evidence-Based Legal Medicine in Reconstructing the Causal Link.

La Clinica terapeutica·2026
Same journal

The therapeutic potential of N-acetylcysteine across multiple organ systems: a narrative review.

La Clinica terapeutica·2026
Same journal

Mesotherapy in Pain Management in Primary Care: A Narrative Review and Practice-Oriented Appraisal.

La Clinica terapeutica·2026
Same journal

Bone Marrow Edema in Rheumatic Diseases: Incidence, Diagnosis, and Therapeutic Implications. A Narrative Review.

La Clinica terapeutica·2026
See all related articles

Hypercholesterolemia contributes to atherosclerosis and cardiovascular disease. HMGCoA reductase inhibitors, like Simvastatin, effectively lower cholesterol and reduce disease risk with minimal side effects.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Hypercholesterolemia is a key factor in atherosclerosis and its cardiovascular complications.
  • Cholesterol-lowering therapies have proven effective in managing atherosclerotic disease progression.
  • Coronary heart disease, a major complication of atherosclerosis, shows reduced incidence and mortality with treatment.

Purpose of the Study:

  • To review the role of HMGCoA reductase inhibitors in managing hypercholesterolemia.
  • To compare different classes of HMGCoA reductase inhibitors.
  • To highlight the efficacy and safety of Simvastatin.

Main Methods:

  • Review of epidemiological observations, experimental, and clinical research.
  • Classification of HMGCoA reductase inhibitors based on chemical structure and activity.

Related Experiment Videos

  • Analysis of clinical studies on cholesterol-lowering effects and side effects.

    • Main Results:

    • HMGCoA reductase inhibitors target the rate-limiting enzyme in cholesterol synthesis.
    • Two main groups of inhibitors exist: inactive lactone prodrugs (e.g., Simvastatin) and active hydroxyacid forms (e.g., Pravastatin).
    • Simvastatin demonstrates significant efficacy in reducing total and LDL-cholesterol with moderate side effects.

    Conclusions:

    • Simvastatin plays a crucial role in treating familial and polygenic hypercholesterolemia.
    • HMGCoA reductase inhibitors are generally safe and effective for cholesterol management.
    • The efficacy of Simvastatin may stem from its higher affinity for the HMGCoA reductase enzyme.